The peptide therapeutics market hit $164 billion in 2026. By 2033, it’ll reach $295 billion — growing at 8.7% annually. GLP-1 drugs alone generated over $36 billion in 2025 (Mounjaro + Zepbound). And the single largest user demographic for GLP-1 medications? Women aged 50-64, with 20% reporting current or past use. The industry is booming on women’s spending. The content and education ecosystem still pretends they don’t exist.
A 2025 RAND analysis found that women aged 50-64 have the highest GLP-1 use overall — 20% reporting current or past use. The menopause market itself is valued at $17.79 billion and projected to reach $24.35 billion by 2030. The FemTech sector (technology and products focused on women’s health) is growing at 15%+ annually. Women control 80% of household healthcare spending decisions.
Yet the peptide education ecosystem — the sites, blogs, and content that shape how consumers discover and evaluate peptide therapy — is built for male biohackers. The market is profiting from women while ignoring them editorially.
Every underserved audience represents an opportunity. Women searching for peptide information encounter male-coded content, give up or turn to unreliable sources, make uninformed decisions, and receive suboptimal care. The sites that fill this gap — with evidence-based, women-specific content — will capture an audience that is actively searching, highly motivated, and dramatically underserved.
The conditions women search for — PCOS (1 in 10 women), perimenopause, autoimmune conditions (80% female), IBS (2x more common in women), hair thinning, skin aging — have near-zero dedicated peptide content. The search volume exists. The content doesn’t.
Yes. The global peptide therapeutics market was $140.9 billion in 2025 and $164 billion in 2026, with projections to reach $294.6 billion by 2033 — a CAGR of 8.73%. GLP-1 drugs (semaglutide, tirzepatide) are the primary growth drivers, with Mounjaro alone generating approximately $23 billion in 2025.
Historical inertia. The peptide space grew from bodybuilding and biohacking communities that were predominantly male. Marketing followed the existing audience. But the data shows women are increasingly the primary consumers — especially for GLP-1 medications, skin peptides, and hormone-related applications. Companies that recognize this shift early will capture significant market share.
Menopause symptom management (estimated $17.79B market), PCOS (10% of reproductive-age women), autoimmune conditions (80% female), skin aging (accelerated post-menopause), fertility (kisspeptin-based IVF triggers), and weight management (women 50-64 are the highest GLP-1 user demographic). Each of these represents a massive, underserved audience.
FemPeptides is the first independent educational resource dedicated to women's peptide therapy. It fills the content gap that exists between the male-coded peptide information ecosystem and the growing female consumer base. By providing evidence-based, women-specific content, it captures an audience that currently has nowhere to go for reliable information.